IntUrolNephrol(2014)46:825–832
DOI10.1007/s11255-013-0521-0
NEPHROLOGY - ORIGINAL PAPER
Pretransplant peritoneal dialysis relative to hemodialysis
improves long-term survival of kidney transplant patients:
a single-center observational study
Mar´ıa O. Lo´pez-Oliva • Begon˜a Rivas • Elia Pe´rez-Ferna´ndez • Marta Ossorio •
Silvia Ros • Carlos Chica • Ana Aguilar • Mar´ıa-Auxiliadora Bajo •
Fernando Escuin • Luis Hidalgo • Rafael Selgas • Carlos Jime´nez
Received:3April2013/Accepted:15July2013/Publishedonline:8September2013
(cid:2)SpringerScience+BusinessMediaDordrecht2013
Abstract hemodialysis (HD)] who proceeded to transplantation
Background Kidney transplantation is the best option for during the period December 1990–2002. Donor and reci-
thetreatmentofend-stagerenaldiseaseintermsofsurvival pient data were collected from our hospital’s clinical reg-
and quality of life. These results can be influenced by the istries. The follow-up period extended to the patient’s
pretransplant dialysis modality. The aim of this study was death, the loss of the allograft, or loss to follow-up. The
to evaluate whether the pretransplantation dialysis modal- end date of the study was set at March 2012.
ity influences patient and allograft survival beyond Results Inthemultivariateanalysis,thelong-termpatient
10 years and examine the potential risk factors associated survival rate was higher for the PD group than for the HD
with the outcomes. group [HR = 2.62 (1.01–6.8); p = 0.04]; however, the
Methods We conducted an observational, retrospective, allograft survival rate was not significantly different
single-center clinical study that included 236 patients [118 between the two groups [HR = 0.68 (0.41–1.10);
undergoing peritoneal dialysis (PD) and 118 undergoing p = 0.12].
Conclusion Pretransplantation dialysis modality is asso-
ciated with long-term patient survival, with outcomes
favoring peritoneal dialysis over hemodialysis. However,
M.O.Lo´pez-Oliva(cid:2)B.Rivas(cid:2)M.Ossorio(cid:2)A.Aguilar(cid:2) thepretransplantdialysismodalitydoesnotinfluencelong-
M.-A.Bajo(cid:2)F.Escuin(cid:2)R.Selgas(cid:2)C.Jime´nez
term graft loss risk.
DepartmentofNephrology,UniversityHospitalLaPaz,IdiPAZ,
Madrid,Spain
Keywords Peritoneal dialysis (cid:2) Hemodialysis (cid:2)
M.O.Lo´pez-Oliva(&) Kidney transplantation (cid:2) Outcomes
ServicioNefrolog´ıa,HospitalUniversitarioLaPaz,IdiPAZ,
PaseodelaCastellana261,28046Madrid,Spain
e-mail:mlopezoliva@hotmail.com
Introduction
E.Pe´rez-Ferna´ndez
DepartmentofBiostatistics,UniversityHospitalLaPaz,IdiPAZ,
End-stage renal disease (ESRD) is a life-threatening dis-
Madrid,Spain
ease that requires the appropriate and sequential selection
S.Ros and ordering of available therapies, dialysis, and trans-
DepartmentofNephrology,UniversityHospitalCarlosHaya, plantation to accomplish the general objective of pro-
Malaga,Spain
longing the patient’s life. Although kidney transplantation
is the best option in terms of positive outcomes (survival
C.Chica
DepartmentofNephrology,HospitalRosales,SanSalvador, and quality of life) [1], the overall results could be influ-
ElSalvador enced by the interaction between previous treatments and
the transplantation. The various dialysis modalities, which
L.Hidalgo
differ in practical terms, can differentially influence the
DepartmentofUrology,UniversityHospitalLaPaz,IdiPAZ,
Madrid,Spain outcomes for transplanted patients [2–11].
123
826 IntUrolNephrol(2014)46:825–832
Thelong-termeffectsoftheinteractionamongthethree The follow-up period (range 2 days–237 months; mean
modalitieshavebeenexploredinanumberofstudies,with duration: 102.1 ± 63.1 months) extended to the patient’s
conflictingresults.Anumberofauthorshavedemonstrated death,thelossoftheallograftrequiringapermanentreturn
thatthedialysismodalitydoesnotaffecttheoutcome[3–6, to dialysis, or loss to follow-up (12 in the HD group and
8, 9, 12]. Other authors have shown increased survival for 14 in the PD group, with a mean follow-up of
patients and grafts treated by peritoneal dialysis (PD) [7, 95.7 ± 57.2 months).The enddate of the study was setto
10, 13, 14] or on the contrary increased graft survival by March 2012.
hemodialysis(HD)[6].Acommonelementofthesestudies Donor and recipient data were collected from our hos-
wastheuseofamedium-termsurvivalanalysis,whichdid pital’s clinical registries. Donor selection and acceptance
notextend the analysisof the patient outcome to 10 years. was performed with similar criteria based on kidney
The importance of considering the long term when evalu- function, absence of clinical kidney abnormalities, and
ating the true success of kidney transplantation is unques- macroscopic examination of grafts, all of which occurred
tionable.A long-term perspective could provide additional overthe12-yearperiod.Pretransplantkidneybiopsieswere
information to the already available data by confirming or not performed in this study group.
disproving the interpretation of the synergies and antago-
nisms among the various ESRD treatments. Immunosuppression regimen
The objective of the present study was to evaluate
whetherthepretransplantationdialysismodalityinfluences The immunosuppression protocol was based on steroids,
allograftandpatientsurvivalbeyond10 yearsandexamine cyclosporine (CyA) or tacrolimus (Tac), and azathioprine
thepotentialriskfactorsassociatedwiththeoutcomes.The (Aza).Aza has been substituted bymycophenolatemofetil
study was conducted on a large series of patients from a (MMF) since 1995. Induction therapy with OKT3 was
university hospital kidney transplantation program from added in high immunological risk patients (panel reactive
December 1990 to 2002. antibody[50 %).
Demographic and clinical variables
Patients and methods
We included recipient variables (age, gender, body mass
The study was conducted according to the strengthening index, pretransplantation time on dialysis, and cause of
the reporting of observational studies in epidemiology kidney disease), donor variables (age, gender, donor type,
(STROBE) methodology [15]. and cause of death in cadaver donors), and transplantation
variables(lengthofstayoftheinitialhospitalization,HLA-
Study design DRmismatches,coldischemiatime,andimmediateuseof
calcineurin inhibitors vs. administration of OKT3).
This was an observational, retrospective, single-center, Other variables related to the intermediate outcome
record-based clinical study. We created two cohorts based were also included: surgical complications over the first
ontheimmediatepretransplantationdialysismodality.The 6 months, incidence of acute rejection, immediate graft
first cohort consisted of patients treated with PD, and the function (defined as immediate diuresis with a decrease of
second cohort consisted of patients treated with HD. at least 30 % in serum creatinine levels 6 h after surgery),
and delayed graft function (DGF), defined as the require-
Patients mentforpost-transplantationdialysisduringthefirstweek.
Laboratory measurements included kidney function eval-
We included all 118 patients who were treated with PD at uated by serum creatinine and 24-h proteinuria levels and
our center and who proceeded to kidney transplantation lipid profiles.
during the period from December 1990 to 2002 (PD
group). This period was selected for reasons related to the Survival analysis
beginningofthecyclosporine(CyA)era.Thecontrolgroup
(HD group) included 118 patients treated with HD who Weperformedanoverallpatientandgraftsurvivalanalysis
received a kidney allograft from the same donor (58 cases that considered causes of death and graft loss. We also
matched by donor) or, in cases where no matching donor performed a specific analysis of graft survival rates com-
was available, the HD recipient who closely preceded or paring patients in the PD and HD groups who shared the
followed each PDcase.Forbothgroups,we onlyincluded same donor to examine the effects of truly paired kidneys
the first allograft received during the study period. by origin.
123
IntUrolNephrol(2014)46:825–832 827
Statistical analysis The initial immunosuppression regimen was similar in
bothgroups.PatientsintheHDgroupreceivedOKT3more
The statistical analysis was performed using SPSS and the frequently, although the differences were not significant.
R, cmprsk statistical package. Qualitative data are
expressed in absolute and relative frequencies [percentage Immediate post-transplantation period
(%)]. Quantitative data are described as mean ± standard
deviation or median and interquartile range (IQR, Patients in the PD group showed earlier kidney function
pp 25–75). recovery with less need for dialysis during the first week.
We used a v2 test or Fisher’s exact test to study the The acute rejection rates were similar for both groups, as
association between qualitative variables. To compare the wasthefrequencyofsurgicalcomplicationsduringthefirst
means of two independent samples, we used Student’s 6 months (Table 2).
t test.
To study patient and graft survival, we calculated the
cumulative incidence of mortality and graft loss in the
presenceofcompetitiveevents.Weconsideredgraftlossto Table1 Demographic and baseline clinical characteristics of recip-
beacompetingeventofdeath,giventhatgraftlosswasthe ientsanddonors
condition being tracked. Death was also considered a PD HD p
competing event of graft loss. We considered censored (n=118) (n=118)
patients all those who dropped out of the study without
Recipients
reaching the primary outcome.
Age,years 43.5±12.4 47.5±13.1 0.01
A univariate analysis was performed to study the pos-
Malegender,(%)[n] 52.5(62) 60.2(71) 0.23
sible risk factors associated with mortality and graft loss.
Primarykidneydisease,(%)[n]
Variableswithclinicaleffectsandavalueofp\0.2inthe
Diabetesmellitus 11(13) 1.6(2) 0.003
univariate analysis were included in a multivariate model
Chronicglomerulonephritis 31.4(37) 33.1(39) 0.78
to estimate the effect of treatment adjusted for other risk
Nephrosclerosis 5.1(6) 8.5(10) 0.3
factors. The univariate analysis was performed with the
Polycystickidneydisease 14.4(17) 10.2(12) 0.32
proportional hazards regression models described by Fine
Tubulointerstitialdisease 15.3(18) 18.6(22) 0.48
and Gray (1999) for quantitative variables and Gray’s test
to compare cumulative incidences between groups. The Systemicdisease 11(13) 4.2(5) 0.05
multivariate model was adjusted by the same method. Unknown 8.5(10) 18.6(22) 0.02
We considered p values \0.05 to be statistically sig- Other 3.4(4) 5.1(6) 0.51
nificant. All statistical tests were two-tailed. Previouskidneytransplant, 2.5(3) 12.7(15) 0.003
(%)[n]
BMI 25.5±4.39 23.8±3.83 0.01
Meandurationof 22.7±14.4 22.9±13.6 0.9
Results
hospitalization,days
Meantimeondialysis,months 27.9±27.9 50.7±67.5 0.001
Table 1 shows the demographic characteristics of all
Donors
patients included in this study. Patients in the PD group
Age,years 45.8±16.2 44.7±14.9 0.6
were younger, spent a shorter time on pretransplantation
Malegender,(%)[n] 65.2(73) 65.5(74) 0.9
dialysis, and had a lower frequency of prior failed allo-
Donortype
grafts.However,othergeneralriskfactorssuchasdiabetes
Cadaverdonor,(%)[n] 95.8(113) 95.8(113) 1
asthecauseofkidneydiseaseandsignificantlyhigherBMI
Non-heartbeatingdonor,(%) 0.8(1) 0.8(1)
(BMI data were available for 55 % of the patients) were
[n]
more frequent among PD patients. The other analyzed
Livingdonor,(%)[n] 3.4(4) 3.4(4)
variables showed no significant differences between the
Causeofdeathincadaverdonors
two groups.
Vascular,(%)[n] 61.5(48) 61.6(45) 0.9
Of the 236 patients, 226 patients received a cadaver
Traumatism,(%)[n] 38.5(30) 38.4(28)
donor allograft, 2 received a non-heart beating donor
Pretransplantcharacteristics
allograft, and 8 received a living donor allograft. These
%HLA-DRmismatch:0/1/2 35/57/8 34/58/8 NS
proportions and other donor characteristics (age, gender,
Coldischemiatime(h) 18±6.5 17.7±6.4 0.71
and cause of death) were similar in both groups. There
werenodifferencesincoldischemiatimesandthenumber Dataaresummarizedusingpercentageandmeans±SD
of HLA-DR mismatches. BMIbodymassindex,PDperitonealdialysis,HDhemodialysis
123
Table2 Immediate post-transplant period and causes of death and conditions were more prevalent in the HD group, with
graftloss infections causing a similar number of deaths between
PD HD p groups(8inthePDgroupvs.7intheHDgroup)(Table 2).
(n=118) (n=118) The long-term patient survival rate was higher for the
PD group than for the HD group (Fig. 1), both overall
Immunosuppression,(%)[n]
(Table 4) and when adjusted for significant univariate
Tacrolimus 43.1(50) 43.6(51) 0.9
variables (Table 3) [PD vs. HD; HR = 2.62 (1.01–6.8);
Cyclosporine 56.9(66) 56.4(66) 0.9
p = 0.04].Recipientagewasanotherindependentvariable
OKT3 22.2(26) 31.9(37) 0.09
inverselycorrelatedwithsurvival[HR = 1.09(1.00–1.17);
Immediategraftfunction,(%)[n] 77.1(91) 63.6(75) 0.01
p = 0.02]. Pretransplantation BMI was also significantly
DGF,(%)[n] 13.9(16) 23.1(27) 0.07
and inversely correlated with survival [HR = 1.12
Acuterejection,(%)[n] 28.2(33) 29.1(34) 0.88
(1.12–1.23), p = 0.019]. The type of calcineurin inhibitor
Surgicalcomplications,(%)[n] 29.3(34) 33.1(39) 0.53
was also a protective factor for patient survival, which
Deaths,(%)[n] 14.4(17) 25.4(30) 0.07
favored tacrolimus over CyA [HR = 2.64 (1.12–6.23);
Vascular 2.5(3) 8.5(10) p = 0.02].
Infections 6.7(8) 5.9(7)
Neoplasia 1.7(2) 7.6(9) Causes of graft loss and allograft survival
Chronichepaticdisease 0.8(1) 0
Unknown 2.5(3) 3.4(4) Seventy-five (75) cases experienced allograft loss over the
Graftloss,(%)(n) 36.4(43) 27.1(32) 0.07 course of the follow-up, 43 in the PD group and 32 in the
Acuterejection 3.4(4) 1.7(2) HD group (p = 0.07). The causes of loss varied and
Chronicnephropathy 23.5(28) 17.8(21) included vascular thrombosis (4 in the PD group and 1 in
Primarygraftthrombosis 3.4(4) 0.8(1) the HD group, p = 0.17) and kidney disease recurrence (6
Others 0.8(1) 6.8(8) in the PD group and 0 in the HD group). The detailed
Kidneydiseaserecurrence 5(6) 0 causes of loss are shown in Table 2. Patients in the PD
group had a higher frequency of graft loss during the first
Boldvaluesindicatethesignificantdata
3 months due to various reasons that included vascular
DGFdelayedgraftfunction(definedastheneedforhemodialysisin
the first week after transplantation), PD peritoneal dialysis, HD thrombosis (4 cases), kidney disease recurrence (3 cases),
hemodialysis and acute rejection (3 cases). In the HD group, the causes
included vascular thrombosis (1 case), acute rejection
Medium- and long-term kidney function outcomes
The overall results for serum creatinine and 24-h protein-
uria levels showed no significant differences between the
two groups throughout the follow-up; however, 24-h pro-
teinurialevelsweresignificantlyhigherinthePDgroup at
12 months(PD:0.8 ± 2.3vs.HD:0.3 ± 0.3;p = 0.03).A
higher kidney disease recurrence was confirmed as the
cause of graft loss in the PD group.
Lipid profile
The serum cholesterol levels were similar throughout the
study, but the serum triglyceride levels at 12 months were
significantly higher in the PD group (PD: 175.3 ± 974 vs.
HD: 147.8 ± 62.9; p = 0.02).
0 50 100 150 200 250
Causes of death and patient survival
Atotalof47deaths(17inthePDgroup and30intheHD
group, p = 0.07) were registered. Deaths resulting from
vascular (3 in the PD group vs. 10 in the HD group) and
neoplastic (2 in the PD group vs. 9 in the HD group)
0.1
8.0
6.0
4.0
2.0
0.0
Time to death
ecnedicnI
evitalumuC
828 IntUrolNephrol(2014)46:825–832
PERITONEAL DIALYSIS
HEMODIALYSIS
Time (months) 50 100 150 200 250
PD 0.052 0.115 0.148 0.148 0.242
HD 0 . 0 7 7 0.183 0.255 0.314 0.314
Fig.1 Cumulative incidence of mortality by pretransplant dialysis
modality
123
Table3 Univariateanalysisfor
Death Graftloss
mortalityandgraftlossrisks
(valuesofpandHR) p HR p HR
Recipientage <0.001 1.08(1.04–1.1) 0.02 0.98(0.96–0.99)
BMI 0.001 1.15(1.06–1.26) 0.54 1.02(0.94–1.11)
Tacrolimus(vs.cyclosporine)use 0.01 2.41(1.22–4.75) 0.15 1.43(0.88–2.34)
Pretransplantdialysismodality 0.04 1.83(1.01–3.3) 0.10 0.68(0.43–1.07)
(HDvs.PD)
Donorage 0.18 0.98(0.96–1) 0.01 1.02(1.01–1.04)
Surgicalcomplications 0.54 0.82(0.43–1.56) 0.01 1.73(1.1–2.73)
OKT3use 0.70 0.88(0.46–1.69) 0.04 1.67(1.02–2.74)
Diabeticnephropathy 0.57 1.32(0.49–3.52) 0.29 1.47(0.71–3.03)
Timeondialysis 0.20 1(0.99–1.01) 0.34 1(0.99–1.01)
Boldvaluesindicatethe Previouskidneytransplant 0.85 1.09(0.4–3) 0.45 1.37(0.59–3.16)
significantdata
Typeofdonor 0.42 0.66(0.24–1.85) 0.89 1.03(0.63–1.71)
BMIbodymassindex,DGF
Coldischemiatime 0.20 1.03(0.98–1.08) 0.45 0.98(0.95–1.02)
delayedgraftfunction(defined
astheneedforhemodialysisin Immediategraftfunction 0.60 1.19(0.62–2.27) 0.41 0.81(0.49–1.33)
thefirstweekafter DGF 0.30 0.64(0.27–1.49) 0.08 1.6(0.93–2.75)
transplantation),PDperitoneal
Acuterejection 0.17 1.51(0.83–2.7) 0.47 1.19(0.73–1.94)
dialysis,HDhemodialysis
(2 cases), and other causes (3 cases). Death with func-
tioning graft was not included among the causes of graft
loss,althoughitwastheprincipalcauseofgraftlossamong
HD patients.
Figure 2 shows the cumulative incidence of graft loss,
which was higher in the PD group due to the higher pre-
mature loss rate. However, the allograft survival rate was
not significantly different between the two groups in the
univariate [HR = 0.7 (0.43–1.1); p = 0.1] and multivari-
ate analysis [HR = 0.68 (0.41–1.10); p = 0.12] of the
pretransplant dialysis modality.
Recipient age [younger: HR = 0.98 (0.96–0.99);
p = 0.02] and donor age [older: HR = 1.02 (1–1.04);
p = 0.01] were associated with a higher allograft loss rate
in the multivariate analysis model. The time spent on
dialysis was not statistical significant (Table 4). 0 50 100 150 200 250
Discussion
Themainresultfromourstudyisthehigher10-yearpatient
survival rate after transplantation for patients treated with
PD than for patients treated with HD. The practice of
performing PD before transplantation could add years of Rumyantzev et al. [13]) that found greater patient survival
life to the transplant and suggests that there could be a [HR = 0.94 (0.91–0.97)] for transplant recipients who
connection between these two therapies. We believe that a received PD immediately before transplantation; the study
high degree of self-care, a fundamental property on which by Molnar et al. [10] (n = 14,508) that demonstrated a
PD is based, could have contributed to this result. Patients patient survival benefit for patients with the pretransplant
treatedwiththistechniquebeforetransplantationcanextend PD modality, with a 43 % [HR = 0.57 (0.38–0.87)]
theirself-careskillsintothepost-transplantationperiod. lower death risk; and the study by Schwenger et al. [14]
Our results are in line with earlier studies, such as the (n = 57,315) that showed greater all-cause 5-year
US Renal Data System study (n = 92,844) (Goldfarb- patient survival in patients treated with PD [HR = 1.10
0.1
8.0
6.0
4.0
2.0
0.0
Time to graft loss
ecnedicnI
evitalumuC
IntUrolNephrol(2014)46:825–832 829
PERITONEAL DIALYSIS
HEMODIALYSIS
Time (months) 50 100 150 200 250
PD 0.189 0.289 0.356 0.475 0.475
HD 0.119 0.199 0.273 0.320 0.320
Fig.2 Cumulative incidence of graft loss by pretransplant dialysis
modality
123
830 IntUrolNephrol(2014)46:825–832
Table4 Multivariateanalysisformortalityandgraftloss respectively], which was in line with the study by Gold-
farb-Rumyantzev(HR = 1.11;p = 0.107andHR = 0.96;
Mortalityrisk p HR HRCI
p = 0.48, respectively) [13].
RecipientBMI 0.019 1.123 1.123–1.239 Furthermore, the improved survival rate among PD
CyAvs.Tacuse 0.02 2.647 1.124–6.232 patientswhencomparedwithHDpatientswasindependent
Recipientage 0.02 1.09 1.009–1.178 of higher allograft loss, which was caused primarily by
Pretransplantdialysismodality 0.04 2.62 1.014–6.804 chronic allograft nephropathy.
(HDvs.PD) Wealsofoundgreaterlong-termsurvivalamongpatients
who were treated with tacrolimus than among those treated
Graftlossrisk p HR HRCI
with CyA. Given that our study was not designed to assess
Recipientage 0.02 0.98 0.96–0.99 this difference, this issue needs to be directly addressed in
Donorage 0.01 1.02 1.00–1.04 future studies in order to be confirmed.
Timeondialysis 0.13 1.00 0.99–1.00 Our long-term graft survival results did not differ
Pretransplantdialysismodality 0.12 0.68 0.41–1.11 between patients treated with pretransplant HD and PD,
(HDvs.PD)
whichwasinlinewiththeadjustedresultsofMolnaretal.
Boldvaluesindicatethesignificantdata [10] [PD HR = 0.95 (0.74–1.23)] and those of other
HR hazard ratio, CI confidence interval, CyA cyclosporine, Tac ta- studies [4–6, 9]. These results, however, differed from
crolimus, PD peritoneal dialysis, HD hemodialysis, BMI body mass those of Goldfarb-Rumyantzev et al. [13], who reported
index
higher graft survival for PD patients [HR = 0.97
(0.94–1.00)],andthoseofSnyderetal.[6],whoobserveda
(1.02–1.18)]. A large US study (n = 22,776) by Snyder lower death-censored graft survival for PD patients
et al. [6], however, reported that patients treated with PD [HR = 1.15(1.04–1.26)]restrictedtothefirst3 monthsof
hadmortalityrates similartothoseofpatients treatedwith follow-up. In our study, patients in the PD group experi-
HD [PD: HR = 0.95 (0.85–1.06)]. encedgraftlossmorefrequentlyandearlierthanpatientsin
However, as in other studies, the different baseline the HD group (as seen in the study by Snyder et al. [6]),
characteristics between our two groups could explain the although this difference was not statistically significant.
different results. As we can see in Table 1, patients on PD Chronic allograft nephropathy was the main cause of graft
spentlesstimeondialysisbeforetransplantation,hadfewer loss in both groups. Graft loss due to primary graft
second transplants, and were younger. Nevertheless, the thrombosis and kidney disease recurrence was more fre-
univariate and multivariate analyses confirmed that reci- quent in the PD group, and it is likely that both causes
pient age, pretransplant PD (vs. HD), pretransplant BMI contributed to the higher rate of early graft failure in the
(independent ofdialysis modality),andtacrolimususe(vs. PD group. Four patients in the PD group and 1 patient in
CyA) were independent risk factors in terms of long-term the HD group lost their graft due to vascular thrombosis;
patient survival. Time on dialysis before transplantation however, these differences were not significant (p = 0.17)
and retransplantation did not influence patient survival. and were not confirmed when examining paired donation
The patients in our PD group had a higher mean pre- allografts (data not shown). Our results were in line with
transplantBMIthanthepatientsintheHDgroup,andBMI those of a preliminary survey by Escuin et al. [18]
was an independent risk factor for long-term patient sur- (n = 1,030,incidenceofgraftthrombosisPDvs.HD:2.17
vival [HR = 1.12 (1.12–1.23)] but not for graft survival. vs. 3.47 %, NS) and those of the study by Pe´rez-Fonta´n
ThemortalityriskforpatientstreatedwithHDisinversely et al. [19] (n = 827, incidence of graft thrombosis PD vs.
related to body size; however, the results for patients HD: 4.7 vs. 6.1 %, NS) who specifically examined this
treated with PD are less consistent. Analyses of data from question and did not confirm an increased risk of primary
the Australia and New Zealand registry (ANZDATA) graft thrombosis in patients treated with PD. On the other
(n = 27,015) have consistently shown a higher mortality hand, Snyder et al. [6] and Murphy et al. [20] (n = 202)
riskforobesepatientstreatedwithPD[16],whichisinline have reported that graft thrombosis is more common in
with our results. Other studies such as the study by Lie- patients treated with PD than in those treated with HD
venseetal.[17](n = 8,016),however,haveshownsimilar [Snyder et al.: HR = 1.59 (1.08–2.36); Murphy et al.:
survival for obese patients treated with PD and for those prevalence of graft thrombosis PD vs. HD: 9.27 vs. 0 %].
treated with HD. Their results, however, should be interpreted cautiously
Another predictor of graft and patient survival evalu- becausethestudybySnyderetal.hadalargeproportionof
ated in our analysis was diabetic nephropathy, which did missingdataonthecauseofgraftfailure,andthestudyby
not influence patient or graft survival [HR = 1.32 (0.49– Murphyetal.wasconductedonasmallpopulationwithno
3.52); p = 0.57 and HR = 1.47 (0.71–3.03); p = 0.29, multivariate analysis, thereby limiting their conclusions.
123
IntUrolNephrol(2014)46:825–832 831
Overall, older donors and younger recipients were Acknowledgments The authors would like to thank Juliette Sieg-
associated with shorter long-term graft survival. However, fried and her team at ServingMed.com for their editing of the man-
uscript. The authors would like to thank Astellas Pharma for their
at the time of our study, our donors and recipients were
unrestrictedgrantforthisstudy.
younger than current donors and recipients. Seventy-two
percent of the donors and recipients were younger than Conflictofinterest Theauthorsdeclarethattheyhavenoconflicts
55 yearsofage,whichsuggeststhatthisresultisirrelevant. ofinterest.
However, older recipients showed better graft survival,
although the main reason for loss was chronic allograft
nephropathy at any age. These findings were independent
References
of those related to dialysis modality.
Theoverallincidenceofacuterejectionwasalsosimilar
1. Dom´ınguez-GilB,delaValent´ınMO,Mart´ınEM,CruzadoJM,
betweenthetwogroupsdespitethehighernumberofgraft PascualJ,Ferna´ndezFG(2010)Presentsituationofliving-donor
losses for acute rejection in the PD group. Patients treated kidneytransplantationinSpainandothercountries:past,present
andfutureofanexcellenttherapeuticoption.Nefrologia30(suppl
with PD have been reported to have better immune
2):3–13
responsestovariousagents[21],whichcaninduceahigher
2. OhtaniS,KomatsudaA,SatohS,TsuchiyaN,SatoK,Habuchi
rejection severity. HT,KatoT(2004)Influenceofpretransplantdialysismodalityon
Pe´rez-Fonta´n [3] was one of the first authors to show thechangeoflymphocytesubsetpopulationsandacuterejection
ratesafterrenaltransplantation.IntJUrol11:825–830
thatpatients treatedwithPDhadalowerriskofDGFthan
3. Fonta´n MP, Rodr´ıguez-Carmona A, Falco´n TG, Moncalia´n J,
patients on HD. Other studies, including ours, have con-
Oliver J, Valde´s F (1996) Renal transplantation in patients
firmed this finding [5, 9–11]. In our case, the immediately undergoingchronicperitonealdialysis.PeritDialInt16:48–51
improved function did not influence long-term graft sur- 4. Bleyer AJ, Burkart JM, Russell GB, Adams PL (1999) Dialysis
modality and delayed graft function after cadaveric renal trans-
vival. The reasons for late losses were independent of the
plantation.JAmSocNephrol10:154–159
kidney function recovery rate and were related to specific
5. CaliskanY,YaziciH,GorguluN,YelkenB,EmreT,TurkmenA
delayed complications. etal(2009)Effectofpretransplantdialysismodalityonkidney
Our study is limited primarily by its single-center nat- transplantationoutcome.PeritDialInt29:S117–S122
6. Snyder JJ, Kasiske BL, Gilbertson DT, Collins AJ (2002) A
ure, which could favor uniformity in various actions but
comparison of transplant outcomes in peritoneal and hemodial-
limits the extrapolation of results. However, this does not
ysispatients.KidneyInt62:1423–1430
lessen the validity of the results, although their interpre- 7. SezerS,KarakanS,O¨zdemirAcarFN,HaberalM(2011)Dial-
tation requires consideration of local conditions and cir- ysis as a bridge therapy to renal transplantation: comparison of
graftoutcomesaccordingtomodeofdialysistreatment.Transpl
cumstances. The retrospective nature of this study was
Proc43:485–487
unavoidable because randomization of the dialysis modal-
8. FreitasC,FructuosoM,MartinsLS,AlmeidaM,PedrosoS,Dias
ityisdifficultanddatafromrandomizedtrialsarecurrently L et al (2011) Posttransplant outcomes of peritoneal dialysis
not available. However, the use of the STROBE method- versushemodialysispatients.TransplProc43:113–116
9. YangQ,ZhaoS,ChenW,MaoH,HuangF,ZhengZetal(2009)
ology in this study can help overcome this difficulty.
Influence of dialysis modality on renal transplant complications
The strengths of our study include the homogeneity of
andoutcomes.ClinNephrol72:62–68
the clinical practice; our hemodialysis, peritoneal dialysis, 10. Molnar MZ, Mehrotra R, Duong U, Bunnapradist S, Lukowsky
and transplantation programs have been conducted by the LR,KrishnanMetal(2012)Dialysismodalityandoutcomesin
kidneytransplantrecipients.ClinJAmSocNephrol7:332–341
same nephrologists, and the daily practice and protocols
11. VanLoo AA,Vanholder RC,Bernaert PR,Vermassen FE,Van
have remained essentially unchanged, although they have
derVennetM,LameireH(1998)Pretransplantationhemodialysis
been regularly updated. Another strength of the study was strategyinfluencesearlyrenalgraftfunction.JAmSocNephrol
the long-term observation, which lasted 22 years. A final 9:473–481
12. O’DonoghueD,ManosJ,PearsonR,ScottP,BakranA,Johnson
strength of our study was the use of competing risk
R et al (1992) Continuous ambulatory peritoneal dialysis and
methods toevaluate thedifferencesintransplant outcomes
renal transplantation: a 10-year experience in a single center.
between both dialysis modalities; a competitive event PeritDialInt12:242–249
survival analysis precludes interferences [22]. 13. Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD, Baird BC,
MStat MS, Alfred K, Cheung AK (2005) The role of pretrans-
In conclusion, our data show that the pretransplantation
plantationrenalreplacementtherapymodalityinkidneyallograft
dialysis modality is associated with long-term patient sur-
andrecipientsurvival.AmJKidneyDis46:537–549
vival, with the results favoring peritoneal dialysis over 14. SchwengerV,Do¨hlerB,MorathC,ZeierM,OpelzG(2011)The
hemodialysis, independently of other conditions (younger roleofpretransplantdialysismodalityonrenalallograftoutcome.
NephrolDialTranspl26:3761–3766
age, lower BMI, and immunosuppression based on tacrol-
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC,
imus). However, pretransplant dialysis modality did not
Vandenbroucke JP (2007) For the STROBE initiative.
influence long-term allograft survival. The strengthening the reporting of observational studies in
123
832 IntUrolNephrol(2014)46:825–832
epidemiology (STROBE) statement: guidelines for reporting 19. Fonta´n MP, Rodr´ıguez-Carmona A, Falco´n TG, Tresancos C,
observationalstudies.AnnInternMed147:573–577 BouzaP,Valde´sF(1998)Peritonealdialysisisnotariskfactor
16. McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR forprimaryvasculargraftthrombosisafterrenaltransplantation.
(2009) Relationship between dialysis modality and mortality. PeritDialInt18:311–316
JAmSocNephrol20:155–163 20. Murphy BG, Hill CM, Middleton D, Doherty CC, Brown JH,
17. Lievense H, Kalantar-Zadeh K, Lukowsky LR, Molnar MZ, Nelson WE et al (1994) Increased renal allograft thrombosis in
DuongU,NissensonAetal(2012)Relationshipofbodysizeand CAPDpatients.NephrolDialTranspl9(8):1166–1169
initialdialysismodalityonsubsequenttransplantation,mortality 21. Vanholder R, Heering P, Van Loo A, Van Biesen W, Lambert
and weight gain of ESRD patients. Nephrol Dial Transpl MC,HesseUetal(1999)Reducedincidenceofacuterenalgraft
27:3631–3638 failureinpatientstreatedwithperitonealdialysiscomparedwith
18. Escuin F, Del Peso G, Pe´rez FM, Rodriguez-Carmona A, hemodialysis.AmJKidneyDis33:934–940
Mart´ınezA,LanuzaMetal(1996)Acomparativesurveyonthe 22. Marlies N, Jager KJ (2012) Survival comparisons between
incidence of kidney graft primary vascular thrombosis among hemodialysis and peritoneal dialysis. Nephrol Dial Transpl 27:
CAPDandhaemodialysispatients[letter].NephrolDialTranspl 3385–3387
11:1896–1897
123
